3篇
您的检索式：作者名="Rodrguez C."
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 1%依柏康唑乳膏治疗皮肤浅部真菌病安全有效:与2%咪康唑乳膏比较的多中心、随机、双盲临床试验显示文摘Background: Eberconazole is a topical, broad-spectrum imidazole derivative, effective in dermatophytoses, candidiasis, and pityriasis treatment. In previous trials, it showed a higher efficacy than clotrimazole in the treatment of dermatophytoses. The purpose of this trial was to evaluate the efficacy of eberconazole 1% cream compared with miconazole 2% cream in the treatment of dermatophytoses. Methods: A multicenter, double-blind, randomized trial was performed in 653 patients with dermatophytoses, randomized to eberconazole 1% cream every 12 h or miconazole 2% cream every 12 h for 4 weeks. Treatment efficacy was assessed on the basis of the percentage of effective response after 4 weeks through mycologic and clinical assessment. Results: Of the 653 patients included in the trial, 360 produced positive baseline mycologic cultures and were included in the efficacy assessment. Clinical efficacy was shown in 76.1% of patients receiving eberconazole and in 75.0% of patients receiving miconazole. The incidence of adverse events related to treatment was 0.91% for eberconazole and 0.92% for miconazole, none being serious, and all being local and transient. Conclusions: Eberconazole 1% cream is an effective treatment for fungal infections produced by dermatophytes, with a good safety and tolerability profile, and can be considered a good alternative for the treatment of dermatophytoses. | Montero T.R. López S. Rodrguez C. 李政霄 | 2006 | 世界核心医学期刊文摘(皮肤病学分册)2006，2，8： | 2 |
| 2 | 多核细胞血管纤维瘤:病例报道 | Blanco Barrios S. Rodrguez Daz E. Alvarez Cuesta C. 崔荣 | 2005 | 世界核心医学期刊文摘(皮肤病学分册)2005，0，8： | 0 |
| 3 | 对有严重胃肠运动障碍患儿实施的肠管和多器官移植显示文摘Background/Purpose: Severe gastrointestinal dysmotility (GID) impairs patients’ quality of life and is almost uniformly fatal after complications of parenteral nutrition. Intestinal and multivisceral transplants have been used as alternative treatment of these disorders. We studied patients with GID treated with transplantation in our center, and reviewed their outcome to determine the therapeutic efficacy of multivisceral transplants. Methods: The transplant database was searched for patients with GID from 1994 to 2001. We excluded patients with Hirschsprung disease, scleroderma, and diabetic enteropathy. We reviewed explanted organs, histochemistry, and immunohistochemistry and classified cases by etiology. Results: We selected 12 children with GID from 124 patients transplanted. Nine presented before 1 year and 3 started with symptoms between 2 and 8 years. By combined clinical and histopathological features, 6 were classified as megacystis microcolon intestinal hypoperistalsis syndrome, 4 as chronic idiopathic intestinal pseudoobstruction, and 2 as intestinal neuronal dysplasias. Six patients died during the follow-up from 21 to 546 days after transplant. The Kaplan-Meier actuarial survival rates were 66.7% at 1 year and 50% at 3 years. Conclusions: Multivisceral transplantation is a valuable therapeutic alternative for children with severe GID who cannot be adequately managed with parenteral nutrition. | Loinaz C. Rodrguez M.M. Kato T. 余晓梅 | 2006 | 世界核心医学期刊文摘(儿科学分册)2006，0，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员